Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

PainReform H1 2024 R&D Expenses $11.4M Due To Phase 3 Trial, Driving Net Loss To $12.8M; G&A Expenses Decrease To $1.5M; Cash Position At $2.8M Following $4M Public Offering In April

Author: Benzinga Newsdesk | August 15, 2024 08:14am

Posted In: PRFX